Published in Cancer on January 15, 2000
Superselective arterial chemotherapy for inoperable metastases in the dura mater and cranium. Interv Neuroradiol (2004) 0.75
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol (1997) 3.76
An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies. J Infect Dis (1979) 3.23
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.06
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol (2003) 2.08
An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. Mol Cell Biol (2000) 1.97
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) 1.89
Fragile-X syndrome: unique genetics of the heritable unstable element. Am J Hum Genet (1992) 1.85
Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol (2001) 1.84
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol (2003) 1.83
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68
The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J (1999) 1.62
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene (2000) 1.57
Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology (2006) 1.55
Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res (1986) 1.53
Colonic adenomas in asymptomatic women with a history of breast cancer. Am J Gastroenterol (1993) 1.44
Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol (2001) 1.42
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
Topological classification of palmar dermatoglyphics. J Ment Defic Res (1970) 1.33
Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol (1998) 1.28
Simplified formulas for detecting linkage with a quantitative character. Ann Hum Genet (1980) 1.28
Age is not a prognostic variable with autotransplants for multiple myeloma. Blood (1999) 1.23
Taxanes in the treatment of breast cancer: a prodigy comes of age. Cancer Invest (1999) 1.19
Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med (1997) 1.15
Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med (1995) 1.14
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol (2001) 1.13
The fertility of patients with clinical stage I testis cancer managed by nerve sparing retroperitoneal lymph node dissection. J Urol (1994) 1.12
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood (1998) 1.12
Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun (2000) 1.10
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood (1996) 1.07
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood (2000) 1.06
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol (1997) 1.06
Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol (2006) 1.06
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol (1998) 1.05
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant (1998) 1.03
The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am (1999) 1.01
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol (1998) 1.01
Monoclonal antibody storage conditions, and concentration effects on immunohistochemical specificity. J Histochem Cytochem (1983) 1.01
Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol (2000) 0.99
Dermatoglyphic sole patterns. a new attempt at classification. Hum Biol (1969) 0.99
Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett (1998) 0.98
Experience with direct molecular diagnosis of fragile X. J Med Genet (1992) 0.95
Evidence for polygenic epistatic interactions in man? Genetics (1984) 0.94
Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Clin Cancer Res (1996) 0.94
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer (2004) 0.93
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol (2004) 0.90
CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. AJNR Am J Neuroradiol (2001) 0.90
The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression. J Neurosci (2000) 0.89
Effects of doxycycline on cancer cells in vitro and in vivo. Adv Dent Res (1998) 0.89
Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. Cancer Res (2001) 0.89
Quercetin down-regulates signal transduction in human breast carcinoma cells. Biochem Biophys Res Commun (1995) 0.88
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol (2002) 0.88
Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol (2005) 0.88
Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer. Blood Cells Mol Dis (1998) 0.87
Genetics of dermatoglyphic patterns on palms. Ann Hum Genet (1971) 0.86
Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer (2000) 0.86
Clonal dominance detected in metastases but not primary tumors of retrovirally marked human breast carcinoma injected into nude mice. Clin Exp Metastasis (1994) 0.85
A study of dermal ridge width in the second (palmar) interdigital area with special reference to aneuploid states. J Ment Defic Res (1967) 0.85
A new marker of maturation in the cervix: the estrogen-regulated 24K protein. Obstet Gynecol (1986) 0.84
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis (2004) 0.84
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Williston Park) (2001) 0.84
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant (2000) 0.83
Dermatoglyphic characteristics of 21-trisomy mosaicism in relation to the fully developed syndrome and normality. J Ment Defic Res (1974) 0.83
Fertility considerations in nerve-sparing retroperitoneal lymph-node dissection. World J Urol (1994) 0.82
Selection bias in clinical trials. Breast Dis (2001) 0.82
Heterogeneity among germ cell tumors of the testis. Semin Oncol (1985) 0.82
Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol (1999) 0.82
Effects of tetracyclines on angiogenesis in vitro. Cancer Lett (2000) 0.81
Establishment in long term culture of megakaryocytic leukemia cells (EST-IU) from the marrow of a patient with leukemia and a mediastinal germ cell neoplasm. Cancer Res (1986) 0.80
Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol (1989) 0.80
Combined anthracycline-taxane regimens in the adjuvant setting. Semin Oncol (2001) 0.79
Steroid hormone receptors in human breast cancer. Adv Cancer Res (1983) 0.79
Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1997) 0.79
A clinico-epidemiological study of sickle cell anaemia in Saudi Arabia. J Trop Pediatr (1991) 0.79
Flow cytometry derived DNA content of the primary lesions of advanced germ cell tumours. Int J Androl (1987) 0.79
High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant (1997) 0.79
Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer. J Clin Oncol (1996) 0.79
Regulation of signal transduction. Adv Enzyme Regul (1995) 0.78
Toward checkmate: biology and breast cancer therapy for the new millennium. Invest New Drugs (1999) 0.78
Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cells. Life Sci (1994) 0.78
DNA content as a prognostic index in gestational trophoblastic neoplasia. Gynecol Oncol (1989) 0.78
Comparative study of sole patterns in chromosomal abnormalities. J Ment Defic Res (1970) 0.78
Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma (1997) 0.78
Presence of an estrogen-regulated protein in endometrial cancer. Obstet Gynecol (1985) 0.78
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group. Cancer (1991) 0.78
Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol (1995) 0.78
Effects of vitamin D3 on proliferation of cancer cells in vitro. Cancer Lett (1997) 0.78